Skip to main content

Clinical Trials

Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-503-5944.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.

Trials

Clinical and Molecular Analysis Of Neoplasms

Pedram, GeramiPedram, Gerami
STU00001127
More Info
Copy

DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY

This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of …
This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods.
  • Consent to have specimens collected as part of a standard of care procedure
  • Have a skin disease diagnosis which researchers want samples of in order to further understand the disease
  • Qualify as a healthy volunteer (a person with no skin disease)
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info
Copy

Epidermolysis Bullosa Clinical Characterization and Outcomes Database

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, …

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

All candidates with a clinical diagnosis of epidermolysis bullosa are eligible for this study.  The subjects can be from any age, male or female without restriction.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00202682
More Info
Copy

(xIRB) Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of lipoproteins (substances made up of fat and protein), cholesterol, and other proteins in the blood. …

The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of lipoproteins (substances made up of fat and protein), cholesterol, and other proteins in the blood.

  • Be 6 to 17 years
  • Have psoriasis or be a healthy volunteer (someone who does not have a skin condition)
  • Participants with psoriasis must have a 6 month or more history of treatment with a topical medication or have a 3 month or less history of treatment with a systemic medication (medication that works throughout the whole body)
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208518
More Info
Copy

Wool Clothing for Atopic Dermatitis

This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks …
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study.

Ages 3 months to 5 years with moderate to severe eczema as determined atinitial visit.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208730
More Info
Copy

XIRB-A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not …

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

12 years or older with plaque or guttate psoriasis predominantly on trunk and/or extremities. Patient needs to be willing to comply with in-office or in-home phototherapy.  
Amin, Ahmad ZAmin, Ahmad Z
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03726489 STU00209270
More Info
Copy

An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness …

This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness and safety of the treatment will be determined by a range of assessments, including biopsies, images, and subjective evaluation of perceived hair growth.

Age 18 and above with a diagnosis of permanent chemotherapy-induced alopecia and agree to use contraception for the duration of the study.

Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03831334 STU00206882
More Info
Copy

Characterization of the microbiome in cutaneous T cell lymphoma

The purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
  • Be between the ages of 18-89
  • Be able and willing to provide informed consent
  • You must not have cutaneous t-cell lymphoma (CTCL)
  • You must not be currently pregnant
  • You must not be on or exposed to systemic antibiotics with 4 weeks of beginning study participation
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00209226
More Info
Copy

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. …

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug).

You could be in this study if:

  • You are 6 to 17 years old
  • A doctor has said you have chronic plaque psoriasis
  • You have had chronic plaque psoriasis for at least 6 months
  • You have taken medication for your psoriasis, but it hasn’t worked

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03451851 STU00209613
More Info
Copy

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who …

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

  • Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
  • Identifying other types of conditions associated with skin disorders
  • Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
  • Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
  • Creating a “Biorepository Specimen Bank” with blood and saliva samples

  • Have a skin condition such as Atopic Dermatitis, Psoriasis, Alopecia, Vitiligo, Hidradenitis Suppurativa and others.
  • You will not be asked to take any medications as part of this study.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00209616
More Info
Copy

Comparison of disease knowledge in dyads of parents and their adolescents with chronic skin disorders

The main goal of this study is to understand how much parents and teenagers know about the teenagers’ chronic skin condition.

This study will enroll children ages 12 to 17 years of age with a diagnosis of psoriasis, atopic dermatitis (eczema), or ichthyosis. Both the child and participating parent must speak English.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00212092
More Info
Copy

Bullying in Pediatric Ichthyosis Patients and its Psychosocial Effects

Pediatric volunteers with ichthyosis and their parents are needed for a study to better understand the frequency and severity of bullying experienced by children with ichthyosis, and the psychosocial effects of this bullying.…

Pediatric volunteers with ichthyosis and their parents are needed for a study to better understand the frequency and severity of bullying experienced by children with ichthyosis, and the psychosocial effects of this bullying.

  • Be 8-17 years old and have ichthyosis
  • Be the parent/guardian of someone 8-17 years old who has ichthyosis
  • Be able to complete a questionnaire about your/your child’s experience with bullying, mental health, and social experiences

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00212124
More Info
Copy

A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTS

This study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors. 
Participants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors. 
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT04088318 STU00211322
More Info
Copy

Impact of immunotherapy-related skin diseases on quality of life

The purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. 
Participants need to be 18 years and older, receiving immunotherapy, and may be experiencing a dermatologic side effect. 
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00212205
More Info
Copy

Tape Strip Analysis in Dermatologic Diseases

The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples …
The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls. 
  • Have a dermatologic disease such as psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, or other rare skin condition
  • Be a healthy volunteer (someone with no dermatologic disease)
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00213591
More Info
Copy

A Prospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the Hospital

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.

  • Be older than 18
  • Be admitted to Northwestern Memorial Hospital or evaluated in the Emergency Department for whom an inpatient dermatology consultation is requested.

Nguyen, CuongNguyen, Cuong
  • Map it 251 E. Huron St.
    Chicago, IL
STU00212714
More Info
Copy

XIRB-Transition Readiness Assessment in Adolescents with Genetic Chronic Skin Disorders

The main goal of this study is to understand the baseline readiness of adolescents with genetic chronic skin condition to transition to an adult model of health care.

  • Be an adolescent between 14-22 years old
  • Have a diagnosis of of a genetic chronic skin condition like ichthyosis, epidermolysis bullosa, and ectodermal dysplasia
  • Must speak English
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00214390
More Info
Copy

Identifying Druggable Targets of Acanthosis Nigricans via Bulk Transcriptomics

This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsies and blood. Photos and medical history will also be collected.&…
This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsies and blood. Photos and medical history will also be collected. 
Participants must have Acanthosis Nigricans or meet the criteria to participate as a healthy control. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00214401
More Info
Copy

Open Label Treatment of Beremagene Geperpavec (B-VEC)

The purpose of this study is to provide use of the gene therapy study drug Beremagene Geperpavec (B-VEC) for participants who have previously completed the parent phase 3 study or for those who were unable to participate in the phase 3 study and would now like to receive treatment …

The purpose of this study is to provide use of the gene therapy study drug Beremagene Geperpavec (B-VEC) for participants who have previously completed the parent phase 3 study or for those who were unable to participate in the phase 3 study and would now like to receive treatment with the study drug.

  • Be willing and able to give consent/assent
  • Have a clinical diagnosis of epidermolysis bullosa
  • Have confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1
  • Be 6 months of age and older at the time of informed consent/assent
  • Women of childbearing age must be willing to use reliable birth control method throughout the treatment duration and for 3 months following the last treatment application

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00215480
More Info
Copy

Medical Outcomes in CHronic Inflammatory skin disease (MOCHI)

The purpose of this study is to collect characteristic data from patients with atopic dermatitis (AD) or other chronic inflammatory skin disorders (CISDs), such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, hidradenitis through an online survey.…

The purpose of this study is to collect characteristic data from patients with atopic dermatitis (AD) or other chronic inflammatory skin disorders (CISDs), such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, hidradenitis through an online survey.

This study is for individuals aged 18 and over who have been diagnosed with atopic dermatitis (i.e. eczema) or other chronic inflammatory skin diseases such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, and hidradenitis.

Chovatiya, RajChovatiya, Raj
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00215502
More Info
Copy

A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells …

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

  • Must be at least 18 years of age
  • Have a confirmed diagnosis of mucosal-dominant pemphigus vulgaris or have a prior positive demoglein 3-ELISA result (a pemphigus vulgaris diagnostic tool) and confirmed by biopsy at the screening visit
  • Have pemphigus vulgaris that has previously been inadequately managed by at least one prior standard therapy
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT04422912 STU00214626
More Info
Copy

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

The purpose of this study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5%strengths), is safe and effective to treat atopic dermatitis (eczema) in children.…
The purpose of this study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5%strengths), is safe and effective to treat atopic dermatitis (eczema) in children.

  • Age 2 - 11 years
  • History of atopic dermatitis (eczema) for at least 3 months
  • Are able to attend regular visits over a 14-month period
  • Willing to discontinue use of other eczema medications during the course of the study

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216006
More Info
Copy

Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects with Extensive Atopic Dermatitis

The purpose of this study is to assess the safety and tolerability (how well treatment is tolerated) of tapinarof cream, 1% (a topical treatment) when applied once daily for 27 days on the surface of the skin of individuals with Atopic Dermatitis (eczema).…
The purpose of this study is to assess the safety and tolerability (how well treatment is tolerated) of tapinarof cream, 1% (a topical treatment) when applied once daily for 27 days on the surface of the skin of individuals with Atopic Dermatitis (eczema).

  • Have been diagnosed with eczema
  • Are male or female between 2 and 17 years of age
  • Have eczema that covers over 25% of the body, not including the scalp
  • Have eczema present for at least 3 months for ages 2 to 5 years old; or have eczema present for at least 6 months for ages 6 years old and above
  • Be able to have a parent(s), or legal representative, provide written informed consent / assent
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216207
More Info
Copy

Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants

The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can …

The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can cause side effects, which are unexpected or unwanted reactions from taking a drug. Study participation is a maximum of 16 weeks. No study drug will be provided for this study, only study procedures (blood draw, specific vital signs) will be performed.

  • Be between 6-18 years of age with a diagnosis of juvenile psoriatic arthritis
  • Be between 6 to <18 years of age, with a diagnosis of pediatric psoriasis
  • Have started ustekinumab treatment for at least 16 weeks prior to participating and have received 3 or more doses of ustekinumab prior to participating
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216219
More Info
Copy

Irritancy and Allergenicity of Synthetic-Melanin-Based Hair Dye Components

The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to …

The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to investigate the possibility of using synthetic melanin as a hair dye as an alternative.

  • Healthy adults ages 18 years or older with skin allergy to PPD
  • Able to list all current medications and medical conditions
  • Capable of giving informed consent.

Gianneschi, NathanGianneschi, Nathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00213915
More Info
Copy

A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.…

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

  • Be 2-17 years old
  • Have a clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months
  • Have involvement of plaque psoriasis on at least 3% of the body, excluding the scalp
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216645
More Info
Copy

Neuropsychologic Assessments of Dupilumab-Treated Adolescents with Moderate-to-Severe Atopic Dermatitis

This study aims to elucidate the burden of atopic dermatitis (AD) in adolescent patients and to look at the impact of dupilumab on that disease burden. The study will measure changes in cognitive and sensory functioning in adolescents with moderate-to-severe AD treated with dupilumab. …

This study aims to elucidate the burden of atopic dermatitis (AD) in adolescent patients and to look at the impact of dupilumab on that disease burden. The study will measure changes in cognitive and sensory functioning in adolescents with moderate-to-severe AD treated with dupilumab.

  • Adolescent (12-17 years of age)
  • Diagnosis of atopic dermatitis (AD) at least 1 year prior to visit
  • No prior use of dupilumab within the past 6 months of visit or screening
  • No other skin diseases
  • No history of any Diagnostic and Statistical Manual-V (DSM-V) psychotic disorder
Paller, AmyPaller, Amy
STU00216931
More Info
Copy

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma

The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102). …

The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102).

  • Be at least 18 years of age
  • Be diagnosed with one of the following types of cancer: Sezary Syndrome (SS), or mycosis fungoides (MF)
  • Have received at least two prior systemic therapies (treatments that use substances that travel through the bloodstream, reaching and affecting cells all over the body)
  • Prior treatment with mogamulizumab
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03902184 STU00215713
More Info
Copy

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, …

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.

  • Patient must be 18 years of age or older.
  • Patient must have pathologically confirmed T or NK cell lymphoma. For CTCL, patients with stage IB disease or greater are eligible.
  • Relapse or refractory disease after at least 1 systemic therapy
  • No prior therapy with ruxolitinib
  • Patient must not be pregnant
  • No concurrent illness/disease or other systemic therapies unrelated to T-cell lymphoma
Choi, JaehyukChoi, Jaehyuk
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02974647 STU00216438
More Info
Copy

Inflammatory Skin Disease Treatment Identification Study (IDENTITY)

As the number of available treatments for psoriasis and atopic dermatitis (AD) grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the …

As the number of available treatments for psoriasis and atopic dermatitis (AD) grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with AD or psoriasis.

  • Patients must be between ages 2 and 85 at time of enrollment.
  • Patients > 18 years of age must be literate in English and be able to complete the patient questionnaires without assistance.
  • Patients must be clinically diagnosed with either AD or psoriasis and has been/is being recommended for system treatment for this condition.
  • Patient must be willing to follow up with institution at required study intervals for assessment of outcome data.
Chovatiya, RajChovatiya, Raj
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00216208
More Info
Copy

Double blinded, split face investigation of the tolerability of two facial cleansing routines for mild to moderate acne

The purpose of this study is to evaluate and compare the efficacy and tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.…

The purpose of this study is to evaluate and compare the efficacy and tolerability of two similar commercially available over the counter acne regimens (Geologie and Proactiv) in individuals with mild to moderate acne vulgaris over a 12-week daily treatment course.

  • 18 years or older
  • No known active skin infection.
  • Presence of mild or moderate acne on face (clinical diagnosis or self-report)
  • Willingness to give written consent and comply with study procedures.
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00217056
More Info
Acne
Copy

Follow Dermatology on